<DOC>
	<DOCNO>NCT01444521</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety first-line chemotherapy cisplatin irinotecan advance gastric cancer , try find optimal dosage combination chemotherapy .</brief_summary>
	<brief_title>Genotype-drive Study Irinotecan-Cisplatin Combination Advanced Gastric Cancer</brief_title>
	<detailed_description>Open label single arm phase II study cisplatin irinotecan patient advance gastric carcinoma previously treat palliative chemotherapy . 40 Patients enrol local trial . The primary objective study determine response rate treatment.Schedule study follow : 8 cycles/14 day irinotecan 125 mg/m2 Day 1 cisplatin 50 mg/m2 Day2 . This study also include genotype investigation UGT1A1 ERCC1 expression order ass determinant efficacy toxicity treatment cisplatin irinotecan study population .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically proven diagnosis adenocarcinoma stomach ( include adenocarcinoma gastroesophageal junction ) Stage III Stage IV disease , accord American Joint Committee Cancer criteria Patients UGT1A1*28 genotype 6/6 6/7 Performance Status 02 Eastern Cooperative Oncology Group ( ECOG ) performance status Scale Previous adjuvant preoperative chemotherapy without contain irinotecan platinum least 6 month enrollment Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) &gt; equal 1.5 * 109/L , platelet &gt; equal 100 *109/L , hemoglobin &gt; equal 10 g/dL . Hepatic : bilirubin &lt; equal 1.5 x ULN ; alkaline phosphatase , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; equal 3 x ULN ( alkaline phosphatase , AST , ALT minor equal 5 x ULN acceptable liver tumor involvement ) , serum albumin &gt; equal to3g/dL . Renal : Calculated creatinine clearance major equal 60 ml/min ( use standard CockcroftGault formula ) . No Prior palliative chemotherapy advance disease Previous radiation therapy allow limited must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete least 30 day study enrollment Known suspect brain metastasis Second primary malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>advanced gastric cancer</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cisplatin</keyword>
</DOC>